Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Phase 1 Terminated 106 enrolled Novartis Pharmaceuticals

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.

Timeline

Start: 2017-09-08
Primary completion: 2020-12-18
Completion: 2020-12-18

Outcome

Outcome not reported

Stopped: “Sponsor's decision”

Publications

Gogoi H, Mansouri S, Jin L. The Age of Cyclic Dinucleotide Vaccine Adjuvants. Vaccines (Basel). 2020 Aug 13;8(3):453. doi: 10.3390/vaccines8030453.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ADU-S100	Other / unclassified	—	Intramuscular
Background	Spartalizumab	Monoclonal antibody	—	Intravenous